Ortho's Monistat 7
This article was originally published in The Tan Sheet
Executive Summary
Application for new Monistat 7 product, which includes both suppository and cream dosage forms, is pending at FDA, the firm said. The combination product is reportedly intended for both external and internal treatment of yeast infections.
You may also be interested in...
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands
People In Brief
Perrigo promotes in pricing, planning